Tag Archive for: #CutaneousTCellLymphoma

4SC AG: Paediatric Investigation Plan waiver for resminostat from the UK MHRA received

/in

Removes the requirement to conduct paediatric clinical studies when the development of the medicine is not needed or is not appropriate for children This supports resminostat’s Marketing Authorisation Application in the UK Planegg-Martinsried, Germany, 15 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with […]

Read more

4SC: Landmark RESMAIN study data presented at the 5th World Congress of Cutaneous Lymphomas

/in

Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cutaneous T-Cell Lymphoma (CTCL) which could significantly change current clinical practice. Planegg-Martinsried, Germany, 11 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma CTCL, today […]

Read more